Back to discover
Disease

Epilepsy, Generalized

Late-stage therapeutic developmentEmerging research
MeSHEpilepsy, Generalized
1
Publications
7
Clinical trials
2022
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q3 2026.
Upcoming Milestones
Clinical Milestones1View
Results expected 1
Activity timeline1

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Stiripentolapproved

Approval — Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive th… (2007)

Clinical trials

6 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
7
All trials
2
Active
5
Late-stage
5
Completed
Late-stage studies

ONO-2017 Phase III Study A Multicenter, Open-label Study in Japanese Patients With Primary Generalized Tonic Clonic Seizures.

Phase 3 · Recruiting · Ono Pharmaceutical Co., Ltd.

Effect of Treating Helicobacter Pylori Infection on Seizure Frequency in Children With Drug-Resistant Idiopathic Generalized Epilepsy

Phase 2/3 · Completed · Sohag University

A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures

Phase 3 · Completed · Pfizer

Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome

Phase 3 · Completed · Lundbeck LLC

TOPAMAX� (Topiramate) Initiated as Monotherapy in Epilepsy (TIME): A Multicenter, Outpatient, Open-Label, Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX� as Monotherapy in the Treatment of Epilepsy in Clinical Practice

Phase 4 · Completed · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recently completed

Effect of Treating Helicobacter Pylori Infection on Seizure Frequency in Children With Drug-Resistant Idiopathic Generalized Epilepsy

Phase 2/3 · Completed · Sohag University

A Phase 3, Randomized, Double-blind, Parallel, Placebo-controlled, Multicenter Study, With Optional Open-label Continuation, Of The Efficacy And Safety Of Vanquix(tm) Auto-injector (Diazepam Injection) For The Management Of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Medical Intervention To Control Episodes Of Acute Repetitive Seizures

Phase 3 · Completed · Pfizer

Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam in Patients With Lennox-Gastaut Syndrome

Phase 3 · Completed · Lundbeck LLC

TOPAMAX� (Topiramate) Initiated as Monotherapy in Epilepsy (TIME): A Multicenter, Outpatient, Open-Label, Study to Evaluate the Dosing, Effectiveness and Safety of TOPAMAX� as Monotherapy in the Treatment of Epilepsy in Clinical Practice

Phase 4 · Completed · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Safety and Efficacy of Clobazam in Subjects With Lennox-Gastaut Syndrome

Phase 2 · Completed · Lundbeck LLC

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2007emaApproval — Stiripentol· Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes3
  • Epilepsy1
  • Epilepsy, Generalized1
  • Epileptic Syndromes1
Leading journals1
  • Epilepsia1
Leading researchers8
  • Auvin S1
  • Cross JH1
  • Galicchio S1
  • Hirsch E1
  • Moshé SL1
  • Nabbout R1
  • Perucca E1
  • Pressler R1
Affiliations (unnormalised)6
  • Aga Khan University1
  • Albert Einstein College of Medicine1
  • Austin Health and Royal Children's Hospital1
  • Bambino Gesu' Children's Hospital1
  • Clinical Neuroscience1
  • Department of Clinical Neurophysiology1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Recurrent conditions characterized by epileptic seizures which arise diffusely and simultaneously from both hemispheres of the brain. Classification is generally based upon motor manifestations of the seizure (e.g., convulsive, nonconvulsive, akinetic, atonic, etc.) or etiology (e.g., idiopathic, cryptogenic, and symptomatic). (From Mayo Clin Proc, 1996 Apr;71(4):405-14)

Identifiers
MeSHEpilepsy, Generalized
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.